Determining the Potential for Efficacy of OTX-601 in Reducing PTSD Symptoms

NCT ID: NCT07316088

Last Updated: 2026-01-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-12-09

Study Completion Date

2026-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is exploring the efficacy of a digital therapeutic app in reducing symptoms of posttraumatic stress disorder (PTSD) in adults.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to conduct a randomized controlled trial to evaluate the efficacy of OTX-601 (intervention) compared to OTX-003 (comparator) in reducing PTSD symptoms from baseline to 7 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

PTSD Post Traumatic Stress Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

OTX-601

A prescription digital therapeutic designed to overcome existing barriers and deliver evidence based treatment for PTSD

Group Type EXPERIMENTAL

OTX-601 Digital Therapeutic

Intervention Type DEVICE

Prescription digital therapeutic designed to overcome existing barriers and deliver evidence-based treatment for PTSD

OTX-003

OTX-003 is a smartphone application developed as a comparator to OTX-601 and designed to match its interface while providing no active PTSD treatment.

Group Type SHAM_COMPARATOR

OTX-003 Comparator app

Intervention Type DEVICE

Comparator designed to match interface of intervention while providing no active treatment.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

OTX-601 Digital Therapeutic

Prescription digital therapeutic designed to overcome existing barriers and deliver evidence-based treatment for PTSD

Intervention Type DEVICE

OTX-003 Comparator app

Comparator designed to match interface of intervention while providing no active treatment.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Posttraumatic stress disorder (PTSD) diagnosis
* Anxiety Sensitivity Index 3 (ASI-3) scores above 24
* PTSD Checklist for DSM-V (PCL-5) scores above 30
* Understands and speaks English
* Access to a smartphone that is connected to the internet

Exclusion Criteria

* Score of 24 or lower on the ASI-3
* Score of 30 and below on the PCL-5
* No PTSD diagnosis
* Active psychosis
* Acute intoxication during study baseline
* Enrolled in another treatment research study
* Medical illness that would prevent the completion of interoceptive exposure exercises
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute of Mental Health (NIMH)

NIH

Sponsor Role collaborator

Florida State University

OTHER

Sponsor Role collaborator

Oui Therapeutics, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Florida State University

Tallahassee, Florida, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Brian Keenaghan

Role: CONTACT

203-200-0482

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Professor of Psychology

Role: primary

850-645-8729

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R44MH136888

Identifier Type: NIH

Identifier Source: secondary_id

View Link

2024-Oui-002-Study2

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Brief Exposure and Exercise for PTSD.
NCT07080606 RECRUITING NA
tDCS and Inhibitory Control in PTSD
NCT06100731 COMPLETED NA
Mindfulness-based Psilocybin Therapy for PTSD
NCT07104916 NOT_YET_RECRUITING PHASE2